Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zofenopril + hydrochlorothiazide versus irbesartan + hydrochlorothiazide in metabolic syndrome patients with uncontrolled essential hypertension
2009-012993-10Phase 3Completed
- Sponsor
- Menarini Group
- Start
- Aug 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in essential hypertension and cardiometabolic risk (CMR) comparing Zofenopril + hydrochlorothiazide with Irbesartan + hydrochlorothiazide (2 arms). Primary endpoint: Office diastolic blood pressure change. Started Aug 2009; status: completed.
02
Drugs
zofenoprilhydrochlorothiazideirbesartan
03
Conditions
essential hypertensioncardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2009-012993-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012993-10.